Health Affairs June 5, 2024
Since 2019, states have enacted prescription drug affordability boards (PDAB) with the asserted intention of lowering drug spending and improving affordability for patients. Variability across states and uncertainty surrounding the implementation of PDAB processes raise questions about the downstream consequences of state governments setting maximum reimbursement rates for drugs purchased in their state. The policy relevance of these questions is heightened as more states debate PDAB legislation, ongoing litigation challenges aspects of PDAB constitutionality, and states with PDABs begin ill-defined affordability review processes and rulemaking that seek to cap drug prices by limiting reimbursement for specified drugs across state-run and/or state-regulated health plans.
In this article, we describe key components of PDAB legislation in four states – Colorado (2021 and...
Today's Sponsors
Today's Sponsor